EBV & HHV6 reactivation is infrequent and not associated with MS clinical course.
Saved in:
| Title: | EBV & HHV6 reactivation is infrequent and not associated with MS clinical course. |
|---|---|
| Authors: | Simpson, S., Taylor, B., Burrows, J., Burrows, S., Dwyer, D. E., Taylor, J., Ponsonby, A.‐L., Blizzard, L., Dwyer, T., Pittas, F., Mei, I. |
| Source: | Acta Neurologica Scandinavica. Nov2014, Vol. 130 Issue 5, p328-337. 10p. |
| Subjects: | Epstein-Barr virus diseases, Human herpesvirus-6 infections, Virus reactivation, Multiple sclerosis, Antiviral agents, Disease progression |
| Abstract: | Background Among the environmental factors associated with multiple sclerosis ( MS) causation, some of the strongest associations are with Epstein-Barr virus ( EBV), and to a lesser extent human herpesvirus 6 ( HHV6). Associations with clinical course are less conclusive, however. Methods We evaluated serum anti- EBV- EA-R IgG and anti- HHV6 IgM, and EBV and HHV6 viral load ( VL) for their associations with relapse, disability, and progression in disability in a prospective cohort of 198 participants with clinically definite MS. Results Anti- EBV- EA-R IgG was detected in 81.8% of cases at study entry, and titers remained essentially unchanged during the study. Anti- HHV6 IgM was detected in only one participant, and EBV- VL (29%) and HHV6- VL (1.8%) were detected in a minority of samples, and where detected levels were low. Our previously demonstrated association between anti- HHV6 IgG and relapse hazard was not affected by adjustment for parameters of reactivation. We found no evidence that any of the viral markers were associated with disability or progression in disability. In relation to relapse, only EBV- VL was positively associated, although this was strongly influenced by a single individual. Conclusion Using a prospective cohort design, we found no convincing evidence that reactivation parameters of EBV or HHV6 were associated with subsequent MS relapse hazard or progression in disability, confirming previous findings, and indicating that herpesvirus reactivation is not an important driver of relapse or disability in this established MS population. [ABSTRACT FROM AUTHOR] |
| Copyright of Acta Neurologica Scandinavica is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Background Among the environmental factors associated with multiple sclerosis ( MS) causation, some of the strongest associations are with Epstein-Barr virus ( EBV), and to a lesser extent human herpesvirus 6 ( HHV6). Associations with clinical course are less conclusive, however. Methods We evaluated serum anti- EBV- EA-R IgG and anti- HHV6 IgM, and EBV and HHV6 viral load ( VL) for their associations with relapse, disability, and progression in disability in a prospective cohort of 198 participants with clinically definite MS. Results Anti- EBV- EA-R IgG was detected in 81.8% of cases at study entry, and titers remained essentially unchanged during the study. Anti- HHV6 IgM was detected in only one participant, and EBV- VL (29%) and HHV6- VL (1.8%) were detected in a minority of samples, and where detected levels were low. Our previously demonstrated association between anti- HHV6 IgG and relapse hazard was not affected by adjustment for parameters of reactivation. We found no evidence that any of the viral markers were associated with disability or progression in disability. In relation to relapse, only EBV- VL was positively associated, although this was strongly influenced by a single individual. Conclusion Using a prospective cohort design, we found no convincing evidence that reactivation parameters of EBV or HHV6 were associated with subsequent MS relapse hazard or progression in disability, confirming previous findings, and indicating that herpesvirus reactivation is not an important driver of relapse or disability in this established MS population. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 00016314 |
| DOI: | 10.1111/ane.12268 |
